ALZpath Inc.

We are pleased to announce that ALZpath Inc. has entered a strategic partnership with Bio-Techne® to advance neurodegenerative disease research! ALZpath's pTau217 antibody will now be incorporated into Bio-Techne's Simple Plex™ assays on the Ella™ platform. This collaboration brings the launch of the Simple Plex Human Phospho-Tau (T217) ALZpath Assay—a tool designed for Alzheimer's disease researchers to achieve accurate, sensitive, and high-precision results. The Ella platform offers researchers decentralized, hands-free immunoassays with results in just 90 minutes, streamlining workflows and enabling rapid insights into biomarkers like pTau217. "As cases of Alzheimer’s disease continue to rise worldwide, this collaboration provides an opportunity to leverage our proprietary pTau217 antibody to advance promising research and development of new treatments,” said Chad Holland, CEO and President of ALZpath. This partnership marks a vital step toward expanding access to advanced diagnostic tools and accelerating the development of new treatments. 📌 Learn more about this exciting partnership in our press release: https://lnkd.in/g9SaGQ3U 📌Visit our website for more details: https://alzpath.bio #ALZpath #BioTechne #NeurodegenerativeDisease #AlzheimersResearch #pTau217

We're incredibly proud to share that ALZpath Inc.’s pTau217 Antibody has been recognized by TIME as one of the "200 Best Inventions of 2024"! As TIME highlights: "Detecting Alzheimer’s disease remains a challenge because its early symptoms can be subtle, but it’s becoming more critical as new treatments emerge. Often, by the time symptoms of memory loss and cognitive decline appear, the condition is more difficult to treat. ALZpath developed the first commercial blood test for pTau217, an early indicator of neurodegeneration, which doctors can now order through specific labs to help identify patients sooner." A huge thank you to our partners at Roche Diagnostics USA for helping make this vision a reality. Together, we're moving the needle on Alzheimer’s care and bringing more hope to people and families affected by this challenging disease.   📌 Read the full story here: https://lnkd.in/eRtb4Urq Curious to learn more about ALZpath? Visit our website here: https://alzpath.bio #ALZpath #AlzheimersAwareness #InnovationInHealthcare #TIMEBestInventions

Thank you, Cognition Therapeutics, Inc., for your recognition! We’re honored to see the ALZpath #pTau217 blood test recognized as one of the TIME Best Inventions of 2024 and thrilled to witness its impact in real-world trials like yours. Here’s to continued progress in Alzheimer’s care and more breakthroughs to come!

The ALZpath Inc. team is excited to be at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference in Madrid, Spain! This global event brings together leading researchers, clinicians, and industry experts to advance the discovery of treatments for Alzheimer’s disease. We’re here to support and present advancements in Alzheimer’s diagnostics, particularly with our pTau217 assay.   Don’t miss the upcoming presentations featuring our proprietary #pTau217 assay: 📌 Plasma pTau217 Alone Is Not Enough for Staging Alzheimer’s Disease  Date: October 31 | Time: 12:15-12:30  (GMT+1) Presented by J.D. Doecke and collaborators   📌 Comparison of One-Step and Two-Step Workflows Using pTau217   Date: October 31 | Time: 15:40-15:55 (GMT+1) Presented by J. Ahn and collaborators   📌 Differential Roles of Alzheimer’s Disease Plasma Biomarkers  Date: November 1 | Time: 14:55-15:10 (GMT+1) Presented by H. Jang and collaborators 📌 The Role of pTau217 in Integrated Amyloid and Tau Staging: Implications for Cognitive Trajectories in Alzheimer’s Disease Date: November 1 | Time: 08:30-08:45 (GMT+1) Presented by D. Shin and collaborators 📌 Timing of Changes in Alzheimer’s Disease Plasma Biomarkers Using Amyloid and Tau PET Clocks Date: November 1 | Time: 08:45-09:00 (GMT+1) Presented by M. Milà-Alomà and collaborators Posters featuring ALZPath pTau217 assay: - P104: Plasma pTau181 and pTau217 Similarly Predict Asymptomatic Amyloid Accumulation - P114: Plasma pTau217 as a Screening Tool for Future AD Neuropathology in Dementia-Free Individuals - P119: Plasma pTau and Amyloid Biomarkers’ Discrimination Accuracy in Alzheimer’s Disease - P123: Is Serum pTau217 a Viable Biomarker for Alzheimer’s Disease? - P124: A Two-Stage Approach to Risk Stratification in Early-Stage Alzheimer’s Disease - P133: Preliminary Evaluation of Plasma ALZpath pTau217 in a Diverse Cohort - LP060: Plasma pTau217, PET, and Cognition in an African American Sample (AA-FAIM Study) - LP072: Clinical Biomarker Scoring System for Anti-Amyloid Clinical Trials We’re proud to support innovative research to make Alzheimer’s diagnostics more accessible and reliable. Stay tuned for updates from #CTAD24! 

TIME’s Best Inventions of 2024 list is out now, and ALZpath is so excited for the ALZpath pTau217 test to be a part of it! #TIMEBestInventionsToday ALZpath Inc. announced that it has been honored in TIME's annual Best Inventions list, which features 200 extraordinary innovations changing our lives. The ALZpath proprietary pTau217 antibody was recognized in the medical care category for its ability to accurately diagnose Alzheimer's disease. 📌 Read the full press release here: https://lnkd.in/dZihrxQz Alzheimer's Association® Dementia Alliance International (DAI) UsAgainstAlzheimer's

ALZpath Inc. is excited to announce our attendance at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, Spain, from October 29 – November 1, 2024! This global event brings together leading researchers, clinicians, and industry experts to advance the discovery of treatments for Alzheimer’s disease. At ALZpath, we are committed to democratizing access to our pTau217 antibody and accelerating the development of innovative diagnostics and treatments. Join us in Madrid as we work together to transform Alzheimer’s research and improve patient outcomes. To connect with us or schedule a meeting, please contact our Chief Business Officer, Jacob Hunter, at jacob@alzpath.bio. We can't wait to meet you at CTAD 2024! #CTAD2024 #CTAD24 #AlzheimersResearch #ALZpath #ClinicalTrials #pTau217

Today, on World Alzheimer's Day, we join the global community in raising awareness and taking action against Alzheimer's and dementia. September is World Alzheimer’s Month, and this year’s theme, Time to Act on Dementia, Time to Act on Alzheimer’s by Alzheimer's Disease International, calls us to address the stigma and misconceptions around this condition. According to Alzheimer's Disease International, 75% of people living with dementia remain undiagnosed, highlighting the need for greater awareness and early detection efforts. At ALZpath, we are proud to contribute to this mission with our groundbreaking work in Alzheimer’s research. Our #pTau217 antibody empowers researchers and clinicians to accelerate the discovery of new treatments and improve patient care. We are committed to driving progress toward early detection and effective therapies. As we observe World Alzheimer’s Month, we stand in solidarity with those affected and remain dedicated to advancing Alzheimer’s research. Together, we can make a real impact and change the narrative surrounding Alzheimer’s disease. #WorldAlzheimersDay #WorldAlzMonth #TimeToActOnAlzheimers #AlzheimersAwareness #ALZpath #Research #Innovation #EndAlzheimers

"The side effects are real, but the drug can buy a person invaluable months or years to spend with loved ones before dementia sets in." – Henrik Zetterberg, MD, PhD, Distinguished Scientific Advisor to ALZpath   On July 25, the European Medicines Agency (EMA) made the decision not to approve lecanemab, a drug that has been shown to slow the progression of cognitive decline in individuals with early-stage Alzheimer’s disease.   In his recent Nature Portfolio article, Dr. Zetterberg emphasizes the importance of involving experienced scientists in regulatory decisions to ensure that innovative treatments reach patients safely and effectively.    Read the full article in Nature: https://lnkd.in/ghb5BpTC   #Alzheimers #Lecanemab #ALZpath #PatientCare #Neuroscience #AlzheimersResearch  

The burden of Alzheimer's disease and related dementias may seem daunting. However, we are pleased to have thought leaders and Health Moonshot Community partners like StartUp Health who are in this fight with us. In a recent interview, our CEO, Chad Holland, shared some perspective on how ALZpath is purpose built to bring p-Tau217 testing to dramatically more of the patients that need it. However, whether it be through partnerships, like the one we recently signed with Roche, or further innovations guided by our outstanding founder team, ALZpath is not going to limit itself to p-tau217. "We're not just going to be a p-tau217 company going forward", says Holland. "I think we're just at this early part of the convergence of neuroscience and medicine and drug development". 📌 Find out more about ALZpath's origins, current on market success and future plans by visiting www.ALZpath.bio 📌 Read the full story by StartUp Health here: https://lnkd.in/g7WjpgAs #pTau217 #Alzheimers #HealthCareInnovation #Diagnostics #Biotechnology #BrainHealth #ALZpath Alzheimer's Association®, Alzheimer's Society, Alzheimer's Foundation of America, Dementia Alliance International, UsAgainstAlzheimer's, Alzheimer's Research UK, Cure Alzheimer's Fund, BrightFocus Foundation

ALZpath Inc. is on a mission to revolutionize Alzheimer’s disease diagnostics, and we’re looking for a Director/Sr. Director of Program & Project Management to help us get there. If you are a strategic thinker with exceptional leadership skills, this role offers the opportunity to drive high-impact projects and collaborate closely with our CEO and senior leadership team. What You’ll Do: - Lead the planning, execution, and monitoring of key programs and projects - Collaborate with senior leadership to develop and execute strategic goals - Oversee cross-functional initiatives and resource allocation across teams - Drive process improvements to support our rapid growth - Build strong relationships with internal teams and external partners - Establish KPIs to assess program performance and deliver key results - Provide leadership and mentorship as our Program & Project Management team grows What We’re Looking For: - 12+ years of experience in project/program management, preferably within biotechnology or life sciences - Strong strategic planning and execution skills - Proven ability to manage multiple high-priority initiatives in a fast-paced environment - Excellent communication, problem-solving, and leadership abilities - PMP or similar certification is a plus 📌View the full job description on our website: www.alzpath.bio/careers #Hiring #BiotechJobs #ProjectManagement #ProgramManagement #AlzheimersDisease #ALZpath #ptau217